<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01490801</url>
  </required_header>
  <id_info>
    <org_study_id>AHOD12B1</org_study_id>
    <secondary_id>COG-AHOD12B1</secondary_id>
    <secondary_id>AHOD12B1</secondary_id>
    <secondary_id>NCI-2012-00089</secondary_id>
    <nct_id>NCT01490801</nct_id>
  </id_info>
  <brief_title>Biomarkers in Blood and Tissue Samples From Patients With Epstein-Barr Virus-Positive Hodgkin Lymphoma</brief_title>
  <official_title>Role of the IL-2 Inducible Tcell Kinase in EBV-HLH and EBV+ Hodgkin's Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Oncology Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Studying samples of blood and tissue from patients with cancer in the laboratory
      may help doctors learn more about changes that occur in DNA and identify biomarkers related
      to cancer.

      PURPOSE: This research trial studies biomarkers in blood and tissue samples from patients
      with Epstein-Barr virus positive Hodgkin lymphoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Evaluate germline DNA from patients with Epstein-Barr virus positive (EBV+) and Hodgkin
           lymphoma (HL) for inducible T-cell kinase (ITK) mutations.

        -  Examine the effects of ITK mutations on expression of the ITK protein.

        -  Determine whether ITK mutations correlate with specific clinical or histopathological
           features of HL.

      OUTLINE: Archived blood and tumor tissue samples are analyzed for germline DNA expression and
      inducible T-cell kinase (ITK) mutations by PCR, IHC, flow cytometry, and western blotting,
      and EBV-encoded RNA (EBER) using in situ hybridization. Each patient's data, such as date,
      sex, age, tumor stage and histology at diagnosis, treatment received, response to treatment,
      development of recurrent disease, date of last follow-up, and outcomes are also collected.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Presence of germline ITK mutations</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Influence of ITK mutations on total expression levels or intracellular localization of the ITK protein</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlation between ITK mutations with specific clinical or histopathological features of HL</measure>
  </primary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Lymphoma</condition>
  <condition>Nonneoplastic Condition</condition>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>DNA analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>RNA analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>cytogenetic analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>in situ hybridization</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>mutation analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>polymerase chain reaction</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>western blotting</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>flow cytometry</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunohistochemistry staining method</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>medical chart review</intervention_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood and Tissue
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Diagnosis of Hodgkin lymphoma.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Diagnosis of Hodgkin lymphoma (HL) meeting the following criteria:

               -  Epstein-Barr virus-positive (EBV+) HL as assessed by positive EBV serology,
                  elevated levels of EBV genome in the blood or tumor tissue following quantitative
                  polymerase chain reaction (PCR) and/or evidence of EBV positivity of pathology
                  samples (EBER+ or LMP+) and, when possible, mixed cellular histology

               -  Young age (&lt; 10 years) at diagnosis

               -  Presence of hemophagocytic lymphohistiocytosis (HLH)

        PATIENT CHARACTERISTICS:

          -  Not specified

        PRIOR CONCURRENT THERAPY:

          -  Not specified
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>9 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kim E. Nichols, MD, BA</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital of Philadelphia</affiliation>
  </overall_official>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 9, 2011</study_first_submitted>
  <study_first_submitted_qc>December 9, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 13, 2011</study_first_posted>
  <last_update_submitted>May 13, 2016</last_update_submitted>
  <last_update_submitted_qc>May 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>childhood Hodgkin lymphoma</keyword>
  <keyword>childhood mixed cellularity Hodgkin lymphoma</keyword>
  <keyword>hemophagocytic lymphohistiocytosis</keyword>
  <keyword>Epstein-Barr virus infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

